Australian Leukaemia Study Group Myeloma II: A randomized trial of intensive combination chemotherapy with or without interferon in patients with myeloma

British Journal of Haematology

Volumn 97, Issue 1, 1997, Pages 38-45

  Joshua, Douglas E ^a   Penny, Ron ^b   Matthews, Jane P ^c   Laidlaw, Christine R ^c   Gibson, John ^a   Bradstock, Ken ^d   Wolf, Max ^c   Goldstein, David ^b  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c PETER MACCALLUM CANCER CENTRE   (Australia)

^d WESTMEAD HOSPITAL   (Australia)

Author keywords

co induction therapy; myeloma; plateau; survival; interferon

Indexed keywords

ANTINEOPLASTIC AGENT; CARMUSTINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RECOMBINANT ALPHA2A INTERFERON;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE MYELOMA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL;

EID: 0030936464     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.1997.9942643.x     Document Type: Article

References (15)

1. Aapro, M.S., Alberts, D.S. & Salmon, S.E. (1983) Interactions of human leukocyte interferon with vinca alkaloids and other chemotherapeutic agents against human tumors in clonogenic assay. Cancer Chemotherapy and Pharmacology, 10, 161-166.
2. Ahre, A., Bjorkholm, M. & Mellstedt, H. (1984) Human leukocyte interferon and intermittent high-dose melphalan/prednisone administration in the treatment of multiple myeloma: a randomized clinical trial. Cancer Treatment Reports, 68, 1331-1338.
3. Avvisati, G., Petrucci, M.T. & Mandelli, F. (1995) The role of biotherapies (interleukins, interferons and erythropoietin) in multiple myeloma. Bailliere's Clinical Haematology, 8, 815.
4. Balkwill, F.R. & Moody, E.M. (1985) Positive interactions between human interferon and cyclophosphamide or adriamycin in a human tumor model system. Cancer Research, 44, 906-908.
5. Casassus, P., Pegourie-Bandelier, B., Sadoun, A., Maloisel, F., Autrand Benboubker, L., Quilichini, R., Gardembas, A., Maisonneuve, M., Payen, C., Fain, O., Lamy, T., Desablens, B., Janvier, M., Mahe, B., Harousseau, J.L., for KIF Trial. Abicenne Hospital, Bobigny, France (1995) Randomized comparison of interferon-α with VMCP/VBAP regimen as the induction phase of untreated multiple myeloma: results of the KIF Multicentre Trial. Blood, 86, (Suppl. 1), 441a.
6. Chronic Leukaemia. Myeloma Task Force, National Cancer Institute (1973) Proposed guidelines for protocol studies. II. Plasma cell myeloma Cancer Chemotherapy Reports, 4, 145-158.
7. Cooper, R.B., Dear, K. & McIntyre, R.O. (1993) A randomized trial comparing melphalan/prednisone with or without interferon alfa-2b in newly diagnosed patients with multiple myeloma: a Cancer and Leukaemia Group B study. Journal of Clinical Oncology, 11, 155-160.
8. Joshua, D.E., Penny, R. & Baldwin, R. (1994) The study of combination therapy plus or minus Roferon-A in multiple myeloma. Blood, 84, (Suppl. 1), 179a (abstract 701).
9. Ludwig, H., Cohen, A.M., Polliack, A., Huber, H., Nachbaur, D., Senn, H.-J., Morant, R., Eckhardt, S., Gunczler, P., Seewann, H.L., Schuller, J., Rhyner, K., Cavalli, F. & Fritz, E. (1995) Interferon-alpha for induction and maintenance in multiple myeloma: results of two multicenter randomized trials and summary of other studies. Annals of Oncology, 6, 468-476.
10. Ludwig, H., Cortelezzi, A. & Scheithauer, W. (1986) Recombinant interferon alpha-2c versus polychemotherapy (VMCP) for treatment of multiple myeloma: a prospective randomized trial. European Journal of Cancer Clinical Oncology, 22, 1111-1116.
11. Mandelli, F., Avvisati, G., Amadori, S., Boccadoro, M., Gernone, A., Lauta, V.M., Marmont, F., Petrucci, M.T., Tribalto, M., Vegna, M.L., Dammacco, F. & Pileri, A. (1990) Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy. New England Journal of Medicine, 332, 1430-1434.
12. Mellstedt, H., Ahre, E. & Bjorkholm, G. (1979) Interferon therapy in myelomatosis. Lancet, i, 245-247.
13. α2) or high-dose cyclophosphamide to VBMCP to treat multiple myeloma: results from an ECOG Phase III trial. Blood, 86, (Suppl. 1), 441a.
14. Powles, R., Raje, N., Cunningham, D., Malpas, J., Milna, S., Horton, C., Mehta, J., Singhal, S., Viner, C. & Treleaven, J. (1995) Maintenance therapy for remission in myeloma with intron A following high-dose melphalan and either an autologous bone marrow transplantation or peripheral stem cell rescue. Stem Cells Daytona, 13, 114-117.
15. Westin, J., Rodjer, S. & Turesson, I. (1995) Interferon alfa-2b versus no maintenance therapy during the plateau plateau phase in multiple myeloma: a randomized study. British Journal of Haematology, 89, 561-568.